Abstract
Thyroid cancer is a commonly diagnosed endocrine malignancy with increasing incidence worldwide. Long noncoding RNAs (lncRNAs) are known to function in the invasion and metastasis of thyroid cancer. According to the GSE66783 microarray dataset, long intergenic nonprotein coding RNA 284 (LINC00284) is aberrantly upregulated in thyroid cancer tissues. However, information regarding the specific role of LINC00284 in thyroid cancer remains elusive. Therefore, the current study set out to determine the role of LINC00284 in the development of thyroid cancer, along with an investigation of the underlying molecular mechanism. In parallel with the microarray data from GSE66783, LINC00284 was observed to be expressed at high levels in thyroid cancer cell lines. Moreover, loss-of-function experiments revealed that the downregulation of LINC00284 reduced aldehyde dehydrogenase (ALDH) activity and thyroid cancer cell proliferation, colony formation, and invasiveness, which promoted cell apoptosis. Mechanistically, using dual-luciferase reporter, RNA pull-down, and RNA immunoprecipitation (RIP) assays, LINC00284 was identified to competitively bind to microRNA-30d-5p (miR-30d-5p), which was observed to be expressed at low levels in thyroid cancer tissues and cells and directly targets the oncogene a disintegrin and metalloproteinase 12 (ADAM12). Overexpression of miR-30d-5p exerted tumor-suppressive effects on the malignant activity of thyroid cancer cells, changes that were reversed by LINC00284 overexpression or ADAM12 overexpression. Furthermore, LINC00284 activated the Notch signaling pathway by competitively binding to miR-30d-5p and increasing the expression of ADAM12. Finally, by performing in vivo experiments, we found that LINC00284 silencing or miR-30d-5p overexpression suppressed the tumorigenic ability of thyroid cancer cells and that overexpression of miR-30d-5p inhibited the LINC00284-induced tumorigenesis of thyroid cancer cells. Collectively, our findings indicate that LINC00284 competitively binds to miR-30d-5p and activates the ADAM12-dependent Notch signaling pathway, thereby promoting the development of thyroid cancer.
Highlights
Thyroid cancer is one of the most common endocrine malignancies worldwide, with the incidence increasing steadily in the last few decades [1]
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was conducted to detect the patterns of LINC00284 and miR-30d-5p expression in thyroid cancer cells, and the subsequent results showed that the expression levels of LINC00284 were elevated in five thyroid cancer cell lines (SW1736, FTC133, WRO82, HTh74, and C643) relative to the normal thyroid epithelial cell line HT-ori3 (p < 0.05)
LncRNAs, which function as competing endogenous RNAs (ceRNAs) of miRNAs, possess the ability to regulate the expression of RNA targets through miRNA response elements, whereas a few studies have highlighted the presence of some ceRNA regulatory mechanisms in thyroid cancer [26]
Summary
Thyroid cancer is one of the most common endocrine malignancies worldwide, with the incidence increasing steadily in the last few decades [1]. Thyroid cancer is a heterogeneous group of cancers that are classified into several subtypes, including papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) [3]. Numerous factors, such as genetic changes, growth factors, and radiation, are implicated in the development of PTC, with radiation exposure being the most well-known risk factor [4], while age, tumor size, and histological parameters, including lymph node invasion and distant metastasis, are associated with the prognosis of PTC [5]. LINC00284 was previously reported to function as a tumor-promoting lncRNA in ovarian cancer by enhancing the proliferation, migration, invasion, and tumorigenic ability of ovarian cancer cells [10]. The current study aimed to identify the effect of LINC00284 on thyroid cancer and the associated regulatory network
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
